supp.fit

Docosahexaenoic Acid, Omega-3 Fatty Acids and Zeaxanthin: study protocols

7 study groups took Docosahexaenoic Acid together with Omega-3 Fatty Acids and Zeaxanthin. These are the doses the studies gave. They are not a recommendation.

Docosahexaenoic Acid: what the research found →

Dose per serving from research: Docosahexaenoic Acid

7 study groups in 6 studies say how much Docosahexaenoic Acid participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 71% of 7 study groups.

Daily doseStudy groups
100 mg or less
1
100 mg to 250 mg
1
250 mg to 500 mg
5

Dose per serving from research: Omega-3 Fatty Acids

7 study groups in 6 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 43% of 7 study groups.

Daily doseStudy groups
50 mg or less
1
50 mg to 100 mg
2
100 mg to 250 mg
0
250 mg to 500 mg
0
500 mg to 1 g
3
over 1 g
1

Dose per serving from research: Zeaxanthin

7 study groups in 6 studies say how much Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 mg to 2.5 mg, 86% of 7 study groups.

Daily doseStudy groups
1 mg or less
1
1 mg to 2.5 mg
6

Commonly used together

7 of 7 study groups took Docosahexaenoic Acid, Omega-3 Fatty Acids and Zeaxanthin with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Lutein
7

7 study groups

Study
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
350 mg650 mg2 mg5 years—
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
300 mg100 mg2 mg12 weeks96
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
300 mg100 mg2 mg24 weeks40
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
350 mg650 mg2 mg5 years—
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
100 mg30 mg1 mg1 year—
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
200 mg1.05 g2 mg—10
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
350 mg650 mg2 mg5 years—